(SVRA) Savara - Overview
Stock: Inhaled Immunostimulant, Orphan Lung Therapy, Phase-3 Candidate
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.8% |
| Relative Tail Risk | -4.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 73.54 |
| Character TTM | |
|---|---|
| Beta | 0.721 |
| Beta Downside | 0.114 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.30% |
| CAGR/Max DD | 0.46 |
Description: SVRA Savara December 29, 2025
Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharma focused on rare respiratory disorders. Its lead candidate, molgramostim-an inhaled granulocyte-macrophage colony-stimulating factor-is in Phase 3 trials for autoimmune pulmonary alveolar proteinosis (a-PAP). The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Key metrics as of the most recent filing show a market capitalization of roughly $200 million and a cash runway extending through the end of 2026, providing sufficient liquidity to complete the Phase 3 program without immediate equity dilution. The rare-disease focus aligns with a sector-wide premium: FDA’s orphan-drug designation and accelerated-approval pathways historically lift valuation multiples for comparable biotech firms by 2-3×. Additionally, the broader respiratory-therapeutics market is projected to grow at a CAGR of ~5 % through 2030, driven by an aging population and increasing prevalence of chronic lung conditions.
For a deeper dive into how Savara’s pipeline and financial outlook compare to peers, you might find ValueRay’s analyst tools useful for independent evaluation.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -115.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.70 > 0.02 and ΔFCF/TA -36.33 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.70 > 3% & CFO -99.3m > Net Income -115.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (216.5m) vs 12m ago 2.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.14% > 50% (prev 0.0%; Δ 0.14% > 0%) |
| Interest Coverage Ratio: -57.38 > 6 (EBITDA TTM -117.5m / Interest Expense TTM -2.05m) |
Altman Z'' -15.00
| A: 0.79 (Total Current Assets 128.2m - Total Current Liabilities 16.8m) / Total Assets 140.9m |
| B: -4.09 (Retained Earnings -575.9m / Total Assets 140.9m) |
| C: -0.62 (EBIT TTM -117.7m / Avg Total Assets 189.9m) |
| D: -12.37 (Book Value of Equity -575.8m / Total Liabilities 46.5m) |
| Altman-Z'' Score: -25.29 = D |
What is the price of SVRA shares?
Over the past week, the price has changed by -1.85%, over one month by -4.33%, over three months by +33.17% and over the past year by +86.62%.
Is SVRA a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SVRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.8 | 104% |
| Analysts Target Price | 10.8 | 104% |
| ValueRay Target Price | 7 | 31.3% |
SVRA Fundamental Data Overview February 02, 2026
P/B = 11.63
Revenue TTM = 272.0k USD
EBIT TTM = -117.7m USD
EBITDA TTM = -117.5m USD
Long Term Debt = 29.8m USD (from longTermDebt, last quarter)
Short Term Debt = 49.0k USD (from shortTermDebt, last quarter)
Debt = 29.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.00b USD (1.10b + Debt 29.8m - CCE 124.4m)
Interest Coverage Ratio = -57.38 (Ebit TTM -117.7m / Interest Expense TTM -2.05m)
EV/FCF = -10.12x (Enterprise Value 1.00b / FCF TTM -99.3m)
FCF Yield = -9.89% (FCF TTM -99.3m / Enterprise Value 1.00b)
FCF Margin = -36.5k% (FCF TTM -99.3m / Revenue TTM 272.0k)
Net Margin = -42.5k% (Net Income TTM -115.6m / Revenue TTM 272.0k)
Gross Margin = unknown ((Revenue TTM 272.0k - Cost of Revenue TTM 1.36m) / Revenue TTM)
Tobins Q-Ratio = 7.13 (Enterprise Value 1.00b / Total Assets 140.9m)
Interest Expense / Debt = 4.84% (Interest Expense 1.44m / Debt 29.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -93.0m (EBIT -117.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.65 (Total Current Assets 128.2m / Total Current Liabilities 16.8m)
Debt / Equity = 0.32 (Debt 29.8m / totalStockholderEquity, last quarter 94.4m)
Debt / EBITDA = -0.12 (negative EBITDA) (Net Debt 13.6m / EBITDA -117.5m)
Debt / FCF = -0.14 (negative FCF - burning cash) (Net Debt 13.6m / FCF TTM -99.3m)
Total Stockholder Equity = 133.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.91% (Net Income -115.6m / Total Assets 140.9m)
RoE = -86.60% (Net Income TTM -115.6m / Total Stockholder Equity 133.5m)
RoCE = -72.06% (EBIT -117.7m / Capital Employed (Equity 133.5m + L.T.Debt 29.8m))
RoIC = -57.24% (negative operating profit) (NOPAT -93.0m / Invested Capital 162.4m)
WACC = 8.44% (E(1.10b)/V(1.13b) * Re(8.57%) + D(29.8m)/V(1.13b) * Rd(4.84%) * (1-Tc(0.21)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.71%
Fair Price DCF = unknown (Cash Flow -99.3m)
EPS Correlation: -95.30 | EPS CAGR: -43.25% | SUE: -0.74 | # QB: 0
Revenue Correlation: 25.21 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.40 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+22.6% | Growth Revenue=+0.0%